Advanced Cell Diagnostics' RNAscope reaches milestones

Advanced Cell Diagnostics, a developer of cell- and tissue-based analysis tools, has announced that its RNAscope RNA in situ hybridisation technology has reached two major milestones: the publication of over 100 peer-reviewed papers featuring the technology and an inventory of over 4000 target probes.

RNAscope has the sensitivity to enable researchers to detect in situ single RNA molecules and provide quantitative analysis of gene expression at a single cell level. In addition, the technology provides morphological context by showing spatial and cell-specific expression while preserving tissue architecture.

Gli1 and APOE mRNA expression in mouse brain FFPE tissue using RNAscope 2-plex Chromogenic Reagent Kit.

Since June 2011, RNAscope has been featured in a total of 107 publications. An average of over six papers per month featuring RNAscope have been published so far in 2014 - a rate said to be doubling every year. The papers range from basic research in developmental biology, neuroscience and stem cells to clinical research such as cancer biomarkers, infectious diseases and ophthalmology, in journals such as Nature, Science, Cell, PLOS One, PNAS and Clinical Cancer Research.

“Publications from our customers are particularly exciting, as it shows the growing validation and adoption of our technologies at the forefront of scientific research,” said ADC CSO Xiao-Jun Ma.

In 2011, the company had approximately 500 off-the-shelf probes. With the significant increase in use of RNAscope, ACD has now built a library of over 4000 target probes for numerous species. Probes are designed to order in under two weeks, and in just six months the library has grown by over 1500.

“With our probe catalogue growing by 240% in the last year, targeting more than 4000 genes in many species, it’s a real testament to the demand for our technology, our fast probe development times and the scalability of our platform,” said Ma.

“Together, these two milestones are a comprehensive validation of the effectiveness of RNAscope technology.”

Source